Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

FDA A-fib meeting: FDA will host a public "think tank" meeting on the development of an atrial fibrillation registry on April 27 and 28 at its White Oak, Md., headquarters, Cardiac Electrophysiology and Monitoring Devices Branch Medical Officer Randall Brockman announced at the Boston Symposium on Atrial Fibrillation Jan. 16. The meeting is cosponsored by the Duke Cardiac Safety Research Consortium. More information will be available soon at the consortium's website, 1www.cardiac-safety.org

You may also be interested in...



FDA, Cardiac Safety Research Consortium To Develop AF Ablation Registry

A consortium of academics, manufacturers and government agencies plans to launch a national atrial fibrillation ablation registry, based on input from a variety of stakeholders at a meeting April 27 and 28 at FDA's White Oak, Md., headquarters

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027043

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel